New hope for stomach cancer: Real-World study explores better Second-Line treatments
NCT ID NCT07389876
First seen Feb 05, 2026
Summary
This study looks at different drug combinations for people with advanced stomach or gastroesophageal junction cancer that has not responded to first-line treatment. Researchers will observe 250 participants receiving albumin-bound paclitaxel-based regimens, including immune checkpoint inhibitors or anti-angiogenic drugs. The goal is to see how well these treatments shrink tumors and improve survival in real-world settings.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Wanjing Feng
RECRUITINGShanghai, Shanghai Municipality, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Albumin-bound paclitaxel (a chemotherapy drug) combined with other drugs like immune checkpoint inhibitors or anti-angiogenic drugs
What this could lead to
If successful, this could help identify more effective second-line treatment options for advanced gastric cancer, potentially improving survival and quality of life.
What could go wrong
This is an observational study, not a controlled trial, so results may be less definitive. It is also early-stage research, and benefits may not apply to all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.